{"id":"https://openalex.org/W4404100554","doi":"https://doi.org/10.1183/13993003.congress-2024.pa2178","title":"Efficacy and Safety Analysis of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis","display_name":"Efficacy and Safety Analysis of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis","publication_year":2024,"publication_date":"2024-09-14","ids":{"openalex":"https://openalex.org/W4404100554","doi":"https://doi.org/10.1183/13993003.congress-2024.pa2178"},"language":"en","primary_location":{"id":"doi:10.1183/13993003.congress-2024.pa2178","doi":"https://doi.org/10.1183/13993003.congress-2024.pa2178","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2024.pa2178","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Allergy and immunology","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072054661","display_name":"Changxing Ou","orcid":"https://orcid.org/0000-0002-9993-4617","observed_orcids":["https://orcid.org/0000-0002-9993-4617"]},"institutions":[{"id":"https://openalex.org/I4210098361","display_name":"First Affiliated Hospital of Guangzhou Medical University","ror":"https://ror.org/00z0j0d77","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210098361"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Changxing Ou","raw_affiliation_strings":["1The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China","institution_ids":["https://openalex.org/I4210098361"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Wenmin Lin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210098361","display_name":"First Affiliated Hospital of Guangzhou Medical University","ror":"https://ror.org/00z0j0d77","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210098361"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Wenmin Lin","raw_affiliation_strings":["1The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China","institution_ids":["https://openalex.org/I4210098361"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yue Wu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210098361","display_name":"First Affiliated Hospital of Guangzhou Medical University","ror":"https://ror.org/00z0j0d77","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210098361"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yue Wu","raw_affiliation_strings":["1The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China","institution_ids":["https://openalex.org/I4210098361"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100704869","display_name":"Qingling Zhang","orcid":"https://orcid.org/0000-0002-5287-264X","observed_orcids":["https://orcid.org/0000-0002-5287-264X"]},"institutions":[{"id":"https://openalex.org/I4210098361","display_name":"First Affiliated Hospital of Guangzhou Medical University","ror":"https://ror.org/00z0j0d77","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210098361"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"QingLing Zhang","raw_affiliation_strings":["1The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China","institution_ids":["https://openalex.org/I4210098361"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210098361"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"PA2178","last_page":"PA2178"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10697","display_name":"Vasculitis and related conditions","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10697","display_name":"Vasculitis and related conditions","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12600","display_name":"Eosinophilic Disorders and Syndromes","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mepolizumab","display_name":"mepolizumab","score":0.9890000224113464},{"id":"https://openalex.org/keywords/eosinophilic-granulomatosis-with-polyangiitis","display_name":"eosinophilic granulomatosis with polyangiitis","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hypereosinophilic-syndrome","display_name":"hypereosinophilic syndrome","score":0.7699999809265137},{"id":"https://openalex.org/keywords/anti-il-4-receptor-beta-therapy","display_name":"anti-IL-4 receptor beta therapy","score":0.8149999976158142},{"id":"https://openalex.org/keywords/eosinophil-count","display_name":"eosinophil count","score":0.6679999828338623},{"id":"https://openalex.org/keywords/oral-corticosteroid-dose-reduction","display_name":"oral corticosteroid reduction","score":0.8349999785423279},{"id":"https://openalex.org/keywords/lung-function","display_name":"lung function","score":0.8600000143051147},{"id":"https://openalex.org/keywords/birmingham-vasculitis-activity-score","display_name":"Birmingham Vasculitis Activity Score","score":0.9190000295639038},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.46700000762939453},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.8989999890327454},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.4050000011920929}],"concepts":[{"id":"https://openalex.org/C2781229154","wikidata":"https://www.wikidata.org/wiki/Q1161568","display_name":"Granulomatosis with polyangiitis","level":4,"score":0.9628223180770874},{"id":"https://openalex.org/C2777832160","wikidata":"https://www.wikidata.org/wiki/Q3306175","display_name":"Mepolizumab","level":4,"score":0.9240438342094421},{"id":"https://openalex.org/C2779758542","wikidata":"https://www.wikidata.org/wiki/Q2106364","display_name":"Eosinophilic","level":2,"score":0.6984816789627075},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6514509916305542},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.453269898891449},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2155648171901703},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.1964913010597229},{"id":"https://openalex.org/C2776015282","wikidata":"https://www.wikidata.org/wiki/Q644318","display_name":"Vasculitis","level":3,"score":0.1811804175376892},{"id":"https://openalex.org/C2777037409","wikidata":"https://www.wikidata.org/wiki/Q107238","display_name":"Eosinophil","level":3,"score":0.16646263003349304},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.10575789213180542},{"id":"https://openalex.org/C2776042228","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma","level":2,"score":0.06511282920837402}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1183/13993003.congress-2024.pa2178","doi":"https://doi.org/10.1183/13993003.congress-2024.pa2178","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2024.pa2178","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Allergy and immunology","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.5600000023841858,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2980456502","https://openalex.org/W2795922681","https://openalex.org/W4388140487","https://openalex.org/W2955704458","https://openalex.org/W2741652982","https://openalex.org/W4205359526","https://openalex.org/W3042202894","https://openalex.org/W3179134980","https://openalex.org/W3115629534","https://openalex.org/W2804955203"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"evaluate":[2],"the":[3],"effectiveness":[4],"and":[5,48,90,111,140,151,159,165],"safety":[6,134],"of":[7],"mepolizumab":[8,24],"for":[9],"treating":[10],"eosinophilic":[11],"granulomatosis":[12],"with":[13],"polyangiitis":[14],"(EGPA).":[15],"Method:":[16],"Prospective":[17],"study":[18],"on":[19,39],"20":[20,61],"EGPA":[21,62,143,170],"patients":[22,63],"receiving":[23],"at":[25],"Guangzhou":[26],"Medical":[27],"University's":[28],"First":[29],"Affiliated":[30],"Hospital":[31],"from":[32],"Aug":[33],"2021":[34],"to":[35,55],"Dec":[36],"2023.":[37],"Data":[38],"Birmingham":[40],"Vasculitis":[41],"Activity":[42],"Score":[43],"(BVAS),":[44],"blood":[45],"eosinophils,":[46],"FEV1pred%,":[47],"oral":[49],"corticosteroid":[50],"(OCS)":[51],"doses":[52],"were":[53],"collected":[54],"assess":[56],"treatment":[57],"efficacy.":[58],"Results:":[59],"Of":[60],"(85.0%":[64],"female,":[65],"median":[66],"age":[67],"42),":[68],"after":[69,120],"4":[70,121],"months,":[71,98],"85.0%":[72],"responded":[73],"positively.":[74],"Eosinophil":[75],"count":[76],"significantly":[77],"dropped":[78],"(Z=3.88,":[79],"p<0.001),":[80],"FEV1pred%":[81],"increased":[82],"(Z=2.24,":[83],"P=0.025),":[84],"FeNO":[85],"levels":[86],"fell":[87],"(Z=2.54,":[88],"P=0.011),":[89],"OCS":[91,146,167],"dosage":[92],"reduced":[93,166],"(Z=3.83,":[94],"P<0.001).":[95],"At":[96],"12":[97],"improvements":[99,119],"persisted":[100],"in":[101,116,142,169],"5":[102],"patients.":[103,171],"No":[104],"significant":[105],"difference":[106],"emerged":[107],"between":[108],"standard":[109,158],"(300mg/4w)":[110],"non-standard":[112,160],"(100mg/4w)":[113],"dose":[114],"groups":[115],"clinical":[117],"indicator":[118],"months":[122],"(P>0.05).":[123],"One":[124],"mild":[125],"rash":[126],"event":[127],"occurred":[128],"among":[129],"125":[130],"injections,":[131],"indicating":[132],"good":[133],"profile.":[135],"Conclusion:":[136],"Mepolizumab":[137],"is":[138],"efficacious":[139],"safe":[141],"treatment,":[144],"reducing":[145],"requirement,":[147],"enhancing":[148],"lung":[149],"function,":[150],"showing":[152],"no":[153],"severe":[154],"adverse":[155],"effects.":[156],"Both":[157],"dosing":[161],"effectively":[162],"managed":[163],"symptoms":[164],"use":[168]},"counts_by_year":[],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2025-10-10T00:00:00"}